Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections

Bibliography

• Wisplinghoff H, Bischoff T, Tallent SM, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-17
   PubMed Web of Science ®Google Scholar
• Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005;41(10):1455-60
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
   PubMed Web of Science ®Google Scholar
• Chandwani S, Wentworth C, Burke TA, Patterson TF. Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice. Curr Med Res Opin 2009;25(2):385-93
   PubMed Web of Science ®Google Scholar
• Stevens DA. The new generation of antifungal drugs. Eur J Clin Microbiol Infect Dis 1988;7(6):732-5
   PubMed Web of Science ®Google Scholar
• Eraxis™ (anidulafungin) For Injection. Prescribing information. Pfizer, New York, NY; 2009
   Google Scholar
• Taft CS, Selitrennikoff CP. Cilofungin inhibition of (1-3)-beta-glucan synthase: the lipophilic side chain is essential for inhibition of enzyme activity. J Antibiot (Tokyo) 1990;43:433-7
   PubMed Web of Science ®Google Scholar
• Debono M, Turner WW, Lagrandeur L, Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J Med Chem 1995;38(17):3271-81
   PubMed Web of Science ®Google Scholar
• Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3(1):71-97
   PubMedGoogle Scholar
• Zhanel GG, Karlowsky JA, Harding GAJ, In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitides, and Aspergillus species. Antimicrob Agents Chemother 1997;41(11):863-5
   PubMedGoogle Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36(10):2950-6
   PubMed Web of Science ®Google Scholar
• Nakai T, Uno J, Ikeda F, In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003;47(4):1376-81
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002;51(4):247-55
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Hasumi Y, Ueda K, Effects of micafungin on the morphology of Aspergillus fumigatus. J Electron Microsc (Toyko) 2005;54(1):67-77
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Heath IB, Marrinan J, Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994;38(7):1480-9
   PubMed Web of Science ®Google Scholar
• Thye D, Shepherd B, White RJ, Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers (poster 36). Presented at: 41st Interscience Conference on Antimicrobial Agents; December 2001, Chicago
   Google Scholar
• Dowell JA, Knebel W, Ludden T, Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharm 2004;44(6):590-8
   PubMed Web of Science ®Google Scholar
• Damle BD, Dowell JA, Walsky RL, In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 2009;53(3):1149-56
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharm 2007;47(4):461-70
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Kaever V, Burhenne H, Kielstein JT. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents 2009;34(3):282-3
   PubMed Web of Science ®Google Scholar
• Estes KE, Penzak SR, Anton Calis K, Walsh TJ. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009;29(1):17-30
   PubMed Web of Science ®Google Scholar
• Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother 2008;52(7):2673-6
   PubMed Web of Science ®Google Scholar
• Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 2007;3(4):573-81
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitiene R, Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45(10):2845-55
   PubMed Web of Science ®Google Scholar
• Lat A, Thompson GR, Rinaldi MG, Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. Antimicrob Agents Chemother 2010;54(2):943-4
   PubMed Web of Science ®Google Scholar
• Crandon JL, Banevicius MA, Fang AF, Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 2009;53(12):5102-7
   PubMed Web of Science ®Google Scholar
• Benjamin DK, Driscoll T, Seibel NL, Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50(2):632-8
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008;46(8):2620-9
   PubMed Web of Science ®Google Scholar
• Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2006 to 2007). J Clin Microbiol 2009;47(6):1942-6
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Katiyar SK, Park S, A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008;52(7):2305-12
   PubMed Web of Science ®Google Scholar
• Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005;49(2):767-9
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Chen A, Buhari M, Differential in vitro activity of anidulafungin, caspofungin, and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009;15(3):274-9
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Bocanegra R, In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007;51(5):1616-20
   PubMed Web of Science ®Google Scholar
• Paderu P, Garcia-Effron G, Balashov S, Serum differentially alters the antifungal properties of the echinocandin drugs. Antimicrob Agents Chemother 2007;51(6):2253-6
   PubMed Web of Science ®Google Scholar
• Stein GE, El-Motada M, Smith C, Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp. J Antimicrob Chemother 2010;65(2):374-6
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, In vivo comparison of the pharmacodynamic target among echinocandin drugs and Candida species. Antimicrob Agents Chemother 2010;54(6):2497-506
   PubMed Web of Science ®Google Scholar
• Douglas CM, D'ippolito JA, Shei GJ, Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997;41(11):2471-9
   PubMed Web of Science ®Google Scholar
• Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007;10(3):121-30
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44(3):760-3
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009;53(1):112-22
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Lee S, Park S, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009;53(9):3690-9
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Garcia-Effron G, Lass-Florl C, Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 2010;54(1):426-39
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Diekema DJ, Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 2010;48(5):1592-9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Andes D, Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updates 2010; In press
   Google Scholar
• Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin: evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006;50(9):3160-1
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005;49(12):5146-8
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009;47(10):3323-5
   PubMed Web of Science ®Google Scholar
• Serrano Mdel C, Valverde-Conde A, Chavez M, In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003;45(2):131-5
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Alastruey-Izquierdo A, Cuenca-Estrella M, In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009;53(2):794-5
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008;52(1):321-8
   PubMed Web of Science ®Google Scholar
• Philip A, Odabasi Z, Rodriguez J, In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005;49(8):3572-4
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Jost D, Dierich MP, Lass-Florl C. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob Agents Chemother 2008;52(5):1873-5
   PubMed Web of Science ®Google Scholar
• Bartlett MS, Current WL, Goheen MP, Semisynthetic echinocandins affect cell wall deposition of Pneumosycstis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996;40(8):1811-16
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Bowman JC, Avanessian V, Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005;49(2):721-7
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005;49(2):830-2
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Fu Y, Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008;52(4):1556-8
   PubMed Web of Science ®Google Scholar
• Lewis RE. Pharmacodynamic implications for use of antifungal agents. Curr Opin Pharmacol 2007;7(5):491-7
   PubMed Web of Science ®Google Scholar
• Louie A, Deziel M, Liu W, Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005;49(12):5058-68
   PubMed Web of Science ®Google Scholar
• Gumbo T, Drusano GL, Liu W, Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006;50(11):3695-700
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004;190(8):1464-71
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008;52(2):539-50
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998;42(11):2898-905
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitiene R, Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45(10):2845-55
   PubMed Web of Science ®Google Scholar
• Verweij PE, Oakley KL, Morrissey J, Efficacy of LY303366 against amphotericin B-susceptible and –resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998;42(4):873-8
   PubMed Web of Science ®Google Scholar
• Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44(12):3381-8
   PubMed Web of Science ®Google Scholar
• van de Sande WW, Mathot RAA, Ten Kate MT, Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother 2009;53(5):2005-13
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Hope WW, Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009;53(6):2382-91
   PubMed Web of Science ®Google Scholar
• Spreghini E, Orlando F, Santinelli A, Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother 2009;53(9):4035-9
   PubMed Web of Science ®Google Scholar
• Krause DS, Reinhardt J, Vazquez JA, Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48(6):2021-4
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Boyken L, Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agent Chemother 2005;49(11):4795-7
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82
   PubMed Web of Science ®Google Scholar
• Krause DS, Simjee AE, van Rensburg C, A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39(6):770-5
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Schranz JA, Clark K, A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment fro azole-refractory mucosal candidiasis. J Acqui Immune Defic Syndr 2008;48(3):304-9
   PubMed Web of Science ®Google Scholar
• Walsh T, Herbrecht R, Graham D, Safety and tolerability of combination anidulafungin and liposomal amphotericin B for the treatment of invasive aspergillosis (poster). Presented at the 14th Focus on Fungal Infections Conference; 24 – 26 March 2004; New Orleans, LA
   Google Scholar
• Protocol No. A8851014. Phase 4, open-label pilot study to evaluate the combination of voriconazole and anidulafungin for the treatment of subjects with proven or probable invasive aspergillosis who are intolerant of polyene treatment. Available from: http://www.clinicalstudyresults.org/documents/company-study_9958_0.pdf. [Accessed 2 June 2010]
   Google Scholar
• US National Institutes of Health. Anidulafungin plus voriconazole versus voriconazole for the treatment of invasive aspergillosis. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00531479?term=anidulafungin& cond=aspergillosis&rank=3. [Accessed 1 June 2010]
   Google Scholar
• Vazquez JA. The safety of anidulafungin. Expert Opin Drug Saf 2006;5(6):751-8
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005;45(2):227-33
   PubMed Web of Science ®Google Scholar
• Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005;45(12):1373-82
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007;47(3):305-14
   PubMed Web of Science ®Google Scholar